Core Viewpoint - The company announced that its director, board secretary, and vice president Li Zhe has been subjected to detention measures by the Jinan Municipal Jiyang District Supervisory Committee, but this will not significantly impact the company's normal operations [1] Group 1 - Li Zhe is currently under detention, and during this period, the company's securities affairs representative Wang Xiuting will act as the board secretary [1] - The company maintains a sound governance structure and internal control mechanisms, with all other directors, supervisors, and senior management continuing to perform their duties normally [1] - The production and operational order of the company and its subsidiaries remain normal, indicating stability in business activities despite the situation [1]

Core Viewpoint - The announcement details the profit distribution plan for Ruikang Pharmaceutical Group Co., Ltd. for the fiscal year 2024, which has been approved by the shareholders' meeting held on May 16, 2025, and specifies the cash dividend distribution without issuing new shares [1][2]. Summary by Sections Profit Distribution Plan - The total amount for profit distribution is calculated as 5,937,055.82 yuan, based on a distribution ratio of 0.004 yuan per share for 1,484,263,954 shares [1]. - The cash dividend per share after the distribution will be adjusted to 0.0039456 yuan, calculated as the total cash dividend divided by the total share capital [1]. Changes in Share Distribution - If the total number of shares entitled to profit distribution changes due to convertible bonds, share buybacks, stock option exercises, or new shares from refinancing before the implementation of the profit distribution plan, the total dividend amount will be adjusted accordingly based on the number of shares on the record date [2]. Rights and Dates - The record date for the profit distribution is set for July 7, 2025, and the ex-dividend date is July 8, 2025 [2][3]. - The distribution will be directly credited to the shareholders' accounts through their custodial securities companies [3]. Distribution Recipients - The recipients of the profit distribution will be all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of the record date [3]. Consultation Information - For inquiries regarding the profit distribution, shareholders can contact the company's securities affairs department at the provided address and phone number [3][4].

证券代码：002589 证券简称：瑞康医药 公告编号：2025-035 瑞康医药集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述和重大遗漏。 特别提示： 1、公司总股本 1,504,710,471 股，其中截至目前公司通过回购专户持有的本 公司 20,446,517 股不享有参与利润分配的权利。 公司本次利润分配金额=实际参与分配的总股本×分配比例，即 5,937,055.82 元=1,484,263,954 股×0.004 元/股；本次权益分派实施后除权除息价格计算时，每 股现金红利应以 0.0039456 元（每股现金红利=现金分红总额÷总股本，即 0.0039456 元/股=5,937,055.82÷1,504,710,471）计算，除权除息价格=股权登记日 收盘价格－0.0039456。 3、因此公司 2024 年年度权益分派方案实际为：以公司现有总股本 1,504,710,471 股 剔 除 已 回 购 股 份 20,446,517 股 后 可 参 与 分 配 的 总 股 数 1,484,263,954 股为基数 ...

Core Viewpoint - Ruikang Pharmaceutical has experienced significant growth since its listing in June 2011, with a market value increase from 2.29 billion to 4.59 billion yuan, but recent years have shown a notable decline in both revenue and profit [1][3]. Revenue Analysis - In 2020, Ruikang Pharmaceutical achieved revenue of 27.20 billion yuan, which decreased to 7.97 billion yuan in 2024, representing a cumulative decline of over 70% in the past five years [4]. Profit Analysis - The company's net profit attributable to shareholders was 261 million yuan in 2020, dropping to 21 million yuan in 2024, indicating a continuous decline in profitability [5]. Business Diversification - Ruikang Pharmaceutical's main business segments include pharmaceutical distribution, vaccine and medical device logistics, third-party logistics, medical information services, and more, with pharmaceuticals accounting for 75.16% of revenue and medical devices 22.59% [3]. Market Value Fluctuation - Since its peak market value of 30.81 billion yuan on May 20, 2015, the company's market value has decreased by 26.22 billion yuan, resulting in an 85.10% reduction from its peak [7].

证券代码：002589 证券简称：瑞康医药 公告编号：2025-034 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2024 年 11 月 7 日召开第五届董事会第十次会议，审议通过了《关于回购公司股份方 案的议案》，同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回 购公司部分已发行的人民币普通股（A 股），本次回购股份将用于实施员工持股 计划，回购股份的资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购股份的价格不超过人民币 4.5 元/股（含），具体回购股份的数 量以回购期限届满或回购完毕时实际回购的股份数量为准，实施期限为董事会审 议通过回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 11 月 11 日 在巨潮资讯网披露《第五届董事会第十次会议决议的公告》（2024-036）及《关 于回购公司股份方案暨取得金融机构股票回购专项贷款承诺函的公告》（公告编 号：2024-037）、2024 年 12 月 12 日在巨潮资讯 ...

Core Viewpoint - The proposed equity transfer of 5.05% stake in Ruikang Pharmaceutical by controlling shareholder Zhang Renhua to Yanquan No. 8 private equity fund has been terminated after nine months due to "significant changes in the objective environment," despite an initial transaction value of 162 million yuan [1][2]. Group 1: Transaction Details - The transaction was initially valued at 162 million yuan, with an unusually lenient payment structure: only 5 million yuan (3.1%) was required as the first payment, followed by 50 million yuan within 15 working days after the transfer, and the remaining 106.9 million yuan allowed to be deferred for 90 days [2]. - The Yanquan Wealth management scale was less than 500 million yuan, with all seven operating funds marked as having a "surviving scale of less than 10 million yuan," indicating a significant funding gap for the transaction [3]. Group 2: Obstacles to Completion - Three main obstacles were identified that typically lead to the failure of such agreements: fundraising difficulties, potential undisclosed issues with the equity, and speculative market behavior [4]. - The mismatch between the capital strength of Yanquan Fund and the scale of the transaction was a substantial barrier to completion [4]. Group 3: Market Context - The termination of this agreement is part of a broader trend, with over ten A-share companies announcing similar terminations in May 2025 alone, surpassing the total from the previous four months and accounting for 25% of such cases in 2023 [5]. - The ongoing weak market environment has made it increasingly difficult for buyers to raise funds, particularly for large equity transfers of companies trading below net asset value [5]. Group 4: Shareholder Dynamics - The background of this transfer reflects the difficulties faced by controlling shareholders, as Ruikang Pharmaceutical's stock price has been persistently below net asset value since 2023, limiting their ability to reduce holdings in the secondary market [6]. - The failed transaction was initially seen as a potential solution to the shareholder's predicament, but the design flaws in the transaction ultimately led to its collapse [6].

瑞康医药集团股份有限公司 上市公司名称:瑞康医药集团股份有限公司 股票简称：瑞康医药 股票代码：002589 股票上市地点:深圳证券交易所 信息披露义务人：荆州招商慧泽医药投资合伙企业（有限合伙） 住所或通讯地址：荆州经济技术开发区管委会1号楼招商中心一楼 股份变动性质：股份减少，持股比例降至5%以下 签署日期：2025年6月3日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》、 《上市公司收购管理办法》、 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》及相关 的法律、法规编写本报告。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定，本报 告书已全面披露了信息披露义务人在瑞康医药集团股份有限公司以下简称"瑞康医 药"）中拥有权益的股份变动情况；截止本报告书签署之日，除本报告书披露的持股 信息外，上述信息披露义务人没有通过任何其他方式增加或减少其在瑞康医药拥有 权益的股份。 四、本次权益变动是根据本报告所载明的资料进行的；除信息披露义务人外， 没有委托或授权任何其他人提供未在本报告书中列载的信息和 ...

瑞康医药集团股份有限公司 简式权益变动报告书 上市公司名称:瑞康医药集团股份有限公司 股票简称：瑞康医药 股票代码：002589 股票上市地点:深圳证券交易所 信息披露义务人：荆州招商慧泽医药投资合伙企业（有限合伙） 住所或通讯地址：荆州经济技术开发区管委会1号楼招商中心一楼 股份变动性质：股份减少，持股比例降至5%以下 签署日期：2025年6月3日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》、《上市公司收购管理办法》、 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》及相关 的法律、法规编写本报告。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定，本报 告书已全面披露了信息披露义务人在瑞康医药集团股份有限公司以下简称"瑞康医 药"）中拥有权益的股份变动情况；截止本报告书签署之日，除本报告书披露的持股 信息外，上述信息披露义务人没有通过任何其他方式增加或减少其在瑞康医药拥有 权益的股份。 四、本次权益变动是根据本报告所载明的资料进行的；除信息披露义务人外， 没有委托或授权任何其他人提供未在本报 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-033 瑞康医药集团股份有限公司 关于控股股东终止协议转让公司部分股份的公告 控股股东张仁华女士保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 瑞康医药集团股份有限公司（以下简称"公司"）于近日收到股东张仁华女士 通知，获悉张仁华女士与岩泉8号私募证券投资基金（以下简称"岩泉8号基金"） 就终止协议转让公司部分股份事宜达成一致意见，并签署了《股份转让协议之补 充协议（二）》。现将相关事宜公告如下： 一、协议转让事项概述 2024年8月1日，公司股东张仁华女士与岩泉8号基金签署了《股份转让协议》， 张仁华女士拟通过协议转让方式将其持有的76,000,000股公司股份（占公司总股 本的5.05%）转让给岩泉8号基金，转让价格为2.13元/股，股份转让总价款为人民 币161,880,000元。 根据《中华人民共和国证券法》《上市公司收购管理办法》等相关法律法规 的要求，相关信息披露义务人已就本次股份协议转让事宜履行了信息披露义务， 具体内容详见公司2 ...

Core Viewpoint - The legal opinion confirms that the 2024 Annual General Meeting of Ruikang Pharmaceutical Group Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][11]. Group 1: Meeting Procedures - The meeting was convened based on resolutions from the 14th and 16th meetings of the fifth board of directors held on April 23 and May 6, 2025, respectively [2]. - The notice for the meeting and a supplementary notice were published on April 24 and May 7, 2025, in various financial newspapers and on the official website [2][3]. Group 2: Attendance and Qualifications - The equity registration date for the meeting was May 9, 2025, with a total of 1 shareholder present, representing 185,491,897 shares, which is 12.3274% of the total voting shares [3][4]. - Additionally, 300 shareholders participated via online voting, representing 11,644,879 shares, or 0.7739% of the total voting shares [4]. Group 3: Agenda Items - The agenda included the following items: 1. 2024 Annual Report and its summary 2. 2024 Board of Directors' Work Report 3. 2024 Financial Settlement Report 4. 2024 Supervisory Board Work Report 5. Proposal for the board to issue shares to specific targets via simplified procedures, which requires a special resolution [4][5]. Group 4: Voting Process and Results - The voting was conducted through a combination of on-site written voting and online voting, adhering to legal and regulatory requirements [5][11]. - The voting results showed that 190,902,607 shares (96.8376%) were in favor, 4,593,560 shares (2.3301%) opposed, and 1,640,609 shares (0.8322%) abstained [6][9]. - For minority investors, 5,410,710 shares (46.4643%) were in favor, while 4,593,560 shares (39.4470%) opposed, and 1,640,609 shares (14.0887%) abstained [6][8]. Group 5: Conclusion - The legal opinion concludes that the meeting's procedures, attendance qualifications, and voting processes complied with the Company Law and relevant regulations, affirming the validity of the resolutions passed [11][12].